A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
Phase of Trial: Phase I
Latest Information Update: 05 Jun 2018
At a glance
- Drugs SEphB4-HSA (Primary)
- Indications Cholangiocarcinoma; Liver cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- 05 Jun 2018 Results (n=29) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 23 May 2018 Planned End Date changed from 6 Sep 2019 to 6 Sep 2020.
- 23 May 2018 Planned primary completion date changed from 6 Sep 2018 to 6 Sep 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History